Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists
Identifieur interne : 000F58 ( PascalFrancis/Checkpoint ); précédent : 000F57; suivant : 000F59Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists
Auteurs : Frank Andersohn [Allemagne] ; Edeltraut Garbe [Allemagne]Source :
- Movement disorders [ 0885-3185 ] ; 2009.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
There is growing evidence that the ergot-derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot-derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot-derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot-derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot-derived dopamine agonists may not be limited to heart valves. For nonergot-derived dopamine agonists, no drug safety signals were evident.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:09-0094116Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists</title>
<author><name sortKey="Andersohn, Frank" sort="Andersohn, Frank" uniqKey="Andersohn F" first="Frank" last="Andersohn">Frank Andersohn</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Bremen Institute for Prevention Research and Social Medicine, University of Bremen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>University of Bremen</wicri:noRegion>
<wicri:noRegion>Bremen Institute for Prevention Research and Social Medicine, University of Bremen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Garbe, Edeltraut" sort="Garbe, Edeltraut" uniqKey="Garbe E" first="Edeltraut" last="Garbe">Edeltraut Garbe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Bremen Institute for Prevention Research and Social Medicine, University of Bremen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>University of Bremen</wicri:noRegion>
<wicri:noRegion>Bremen Institute for Prevention Research and Social Medicine, University of Bremen</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Charité Universitaetsmedizin Berlin</wicri:noRegion>
<wicri:noRegion>Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0094116</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0094116 INIST</idno>
<idno type="RBID">Pascal:09-0094116</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F97</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001D22</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000F58</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists</title>
<author><name sortKey="Andersohn, Frank" sort="Andersohn, Frank" uniqKey="Andersohn F" first="Frank" last="Andersohn">Frank Andersohn</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Bremen Institute for Prevention Research and Social Medicine, University of Bremen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>University of Bremen</wicri:noRegion>
<wicri:noRegion>Bremen Institute for Prevention Research and Social Medicine, University of Bremen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Garbe, Edeltraut" sort="Garbe, Edeltraut" uniqKey="Garbe E" first="Edeltraut" last="Garbe">Edeltraut Garbe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Bremen Institute for Prevention Research and Social Medicine, University of Bremen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>University of Bremen</wicri:noRegion>
<wicri:noRegion>Bremen Institute for Prevention Research and Social Medicine, University of Bremen</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Charité Universitaetsmedizin Berlin</wicri:noRegion>
<wicri:noRegion>Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine agonist</term>
<term>Fibrosis</term>
<term>Nervous system diseases</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Pathologie du système nerveux</term>
<term>Stimulant dopaminergique</term>
<term>Fibrose</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There is growing evidence that the ergot-derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot-derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot-derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot-derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot-derived dopamine agonists may not be limited to heart valves. For nonergot-derived dopamine agonists, no drug safety signals were evident.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ANDERSOHN (Frank)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GARBE (Edeltraut)</s1>
</fA11>
<fA14 i1="01"><s1>Bremen Institute for Prevention Research and Social Medicine, University of Bremen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>129-133</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000186473060210</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>19 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0094116</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>There is growing evidence that the ergot-derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot-derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot-derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot-derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot-derived dopamine agonists may not be limited to heart valves. For nonergot-derived dopamine agonists, no drug safety signals were evident.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Fibrose</s0>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Fibrosis</s0>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Fibrosis</s0>
<s5>10</s5>
</fC03>
<fN21><s1>068</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Allemagne</li>
</country>
</list>
<tree><country name="Allemagne"><noRegion><name sortKey="Andersohn, Frank" sort="Andersohn, Frank" uniqKey="Andersohn F" first="Frank" last="Andersohn">Frank Andersohn</name>
</noRegion>
<name sortKey="Garbe, Edeltraut" sort="Garbe, Edeltraut" uniqKey="Garbe E" first="Edeltraut" last="Garbe">Edeltraut Garbe</name>
<name sortKey="Garbe, Edeltraut" sort="Garbe, Edeltraut" uniqKey="Garbe E" first="Edeltraut" last="Garbe">Edeltraut Garbe</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F58 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000F58 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PascalFrancis |étape= Checkpoint |type= RBID |clé= Pascal:09-0094116 |texte= Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |